The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy

Overview of attention for article published in Kidney International, November 2020

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (96th percentile)

Mentioned by

news: 1 news outlet
blogs: 2 blogs
policy: 1 policy source
twitter: 182 X users
patent: 1 patent
facebook: 3 Facebook pages

f1000: 1 research highlight platform
video: 1 YouTube creator
guideline: 1 clinical guideline source
bluesky: 3 Bluesky users
podcasts: 1 podcast

Readers on

mendeley: 138 Mendeley

So far, Altmetric has seen 253 X posts from 182 X users, with an upper bound of 531,164 followers.

因みに元研究のSTARMEN試験 Kidney Int. 2021 https://t.co/srsHbkemxs 知らなんだ

📊 Essai STARMEN : GEM avec syndrome néphrotique CYC-CS 🆚 Tacro 9 mois + RTX (1 g à M6) 📅 Rémission à M24 : 84 % vs 58 % 🧪 Réponse + rapide avec CYC-CS ⚠️ + d’EIs mais SAEs comparables 🔁 RTX ↓ rechutes mais effet retardé 📚 https://t.co/saAexwU9…

RT @AmbrizMau: En pacientes adultos con NEFROPATÍA MEMBRANOSA, el tratamiento con corticoide y ciclofosfamida indujo significativamente más…

RT @NefrarC: STARMEN trial 💉💊 en Glomerulopatía membranosa primaria🧐 Ciclofosfamida+Corticoesteroides Vs Tacrolimus+Rituximab Remisión(parc…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 249 additional X posts.